| Beta carotene | cardiovascular prevention, in all type of patients | vs placebo | cardiovascular events by 31% suggested Cardiovascular death by 28% suggested stroke (fatal and non fatal) by 74% suggested Coronary event by 80% suggested All cause death by 15% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.69 [0.62 0.78] | p=0.04 | 0 | 60118 | 3 | PHS beta carotene, WHS beta carotene, WACS beta-caroten, | | Cardiovascular death | 0.72 [0.67 0.77] | p=0.04 | 0 | 109186 | 6 | ATBC beta carotene, CARET beta carotene, NSCP (Green) beta carotene, PHS beta carotene, WHS beta carotene, WACS beta-caroten, | | stroke (fatal and non fatal) | 0.26 [0.23 0.29] | p=0.04 | 0 | 60118 | 3 | PHS beta carotene, WHS beta carotene, WACS beta-caroten, | | ischemic stroke | 1.12 [0.88 1.42] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | Coronary event | 0.20 [0.18 0.23] | p=0.04 | 0 | 60118 | 3 | PHS beta carotene, WHS beta carotene, WACS beta-caroten, | | Coronary death | no data | | Non fatal MI | 1.09 [0.84 1.41] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | All cause death | 0.85 [0.78 0.92] | p=0.04 | 0 | 81858 | 6 | CARET beta carotene, SCP beta carotene, NSCP (Green) beta carotene, PHS beta carotene, WHS beta carotene, WACS beta-caroten, | | Non fatal stroke | 1.10 [0.86 1.41] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | Haemmorhagic stroke | 2.13 [0.92 4.93] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, |
| Trial | Studied treatment | Control | Patients |
|---|
| ATBC beta carotene, 1994 | beta carotene 20mg four times daily | placebo | male smokers 50 to 69 years of age from southwestern Finland | | CARET beta carotene, 1996 | combination of
30 mg of beta carotene per day and 25,000 IU of retinol
(vitamin A) in the form of retinyl palmitate per day | placebo | smokers, former smokers, and workers
exposed to asbestos | | SCP beta carotene, 1990 | beta carotene 50mg four times daily | placebo | Age <85 years (most <65 years); previous
non-melanoma skin cancer; 69% male | | NSCP (Green) beta carotene, 1999 | beta carotene 30mg four times daily | placebo | residents of Nambour | | PHS beta carotene, 1996 | beta carotene 50 mg on alternate days | placebo | male physicians, 40 to 84 years of age with no history of cancer (except
nonmelanoma skin cancer), myocardial infarction, stroke, or transient
cerebral ischemia | | WHS beta carotene, 1999 | beta carotene 50mg four times daily | placebo | female health professionals, aged 45 years or
older and without a history of cancer (except nonmelanoma
skin cancer), coronary heart disease, or
cerebrovascular disease | | WACS beta-caroten, 2007 | beta carotene (Lurotin) 50 mg every two days
| placebo
| female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors) |
| |
| Beta carotene | cardiovascular prevention, in primary prevention | vs placebo | cardiovascular events by 68% suggested Cardiovascular death by 33% suggested stroke (fatal and non fatal) by 86% suggested Coronary event by 88% suggested All cause death by 26% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.32 [0.27 0.39] | p=0.04 | 0 | 51947 | 2 | PHS beta carotene, WHS beta carotene, | | Cardiovascular death | 0.67 [0.62 0.73] | p=0.04 | 0 | 99394 | 4 | ATBC beta carotene, CARET beta carotene, PHS beta carotene, WHS beta carotene, | | stroke (fatal and non fatal) | 0.14 [0.12 0.16] | p=0.04 | 0 | 51947 | 2 | PHS beta carotene, WHS beta carotene, | | ischemic stroke | no data | | Coronary event | 0.12 [0.10 0.14] | p=0.04 | 0 | 51947 | 2 | PHS beta carotene, WHS beta carotene, | | Coronary death | no data | | Non fatal MI | no data | | All cause death | 0.74 [0.66 0.82] | p=0.04 | 0 | 70261 | 3 | CARET beta carotene, PHS beta carotene, WHS beta carotene, | | Non fatal stroke | no data | | Haemmorhagic stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| ATBC beta carotene, 1994 | beta carotene 20mg four times daily | placebo | male smokers 50 to 69 years of age from southwestern Finland | | CARET beta carotene, 1996 | combination of
30 mg of beta carotene per day and 25,000 IU of retinol
(vitamin A) in the form of retinyl palmitate per day | placebo | smokers, former smokers, and workers
exposed to asbestos | | PHS beta carotene, 1996 | beta carotene 50 mg on alternate days | placebo | male physicians, 40 to 84 years of age with no history of cancer (except
nonmelanoma skin cancer), myocardial infarction, stroke, or transient
cerebral ischemia | | WHS beta carotene, 1999 | beta carotene 50mg four times daily | placebo | female health professionals, aged 45 years or
older and without a history of cancer (except nonmelanoma
skin cancer), coronary heart disease, or
cerebrovascular disease |
| |
| Beta carotene | cardiovascular prevention, in secondary prevention | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.09 [0.95 1.26] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | Cardiovascular death | 1.15 [0.94 1.41] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | stroke (fatal and non fatal) | 1.18 [0.93 1.48] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | ischemic stroke | 1.12 [0.88 1.42] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | Coronary event | 0.96 [0.81 1.14] | p=1.00 | 0 | 9926 | 2 | WACS beta-caroten, ATBC 2nd prev subgroup (b carotene), | | Coronary death | 1.03 [0.75 1.41] | p=1.00 | 0 | 1755 | 1 | ATBC 2nd prev subgroup (b carotene), | | Non fatal MI | 1.00 [0.82 1.23] | p=1.00 | 0 | 9926 | 2 | WACS beta-caroten, ATBC 2nd prev subgroup (b carotene), | | All cause death | 1.03 [0.90 1.18] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | Non fatal stroke | 1.10 [0.86 1.41] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, | | Haemmorhagic stroke | 2.13 [0.92 4.93] | p=1.00 | 0 | 8171 | 1 | WACS beta-caroten, |
| Trial | Studied treatment | Control | Patients |
|---|
| WACS beta-caroten, 2007 | beta carotene (Lurotin) 50 mg every two days
| placebo
| female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors) | | ATBC 2nd prev subgroup (b carotene), 1998 | synthetic beta carotene 20 mg daily | placebo
| patients enroled in the ATBC trial and
who had angina pectoris in the Rose chest
pain questionnaire at baseline
|
| |
| Vitamin c | cardiovascular prevention, in all type of patients | vs placebo | ischemic stroke by 15% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.00 [0.91 1.09] | p=1.00 | 0 | 22812 | 2 | WACS vitamin C, PHS II vitamin C, | | Cardiovascular death | 1.04 [0.91 1.19] | p=1.00 | 0 | 22812 | 2 | WACS vitamin C, PHS II vitamin C, | | stroke (fatal and non fatal) | 0.88 [0.76 1.01] | p=1.00 | 0 | 22812 | 2 | WACS vitamin C, PHS II vitamin C, | | ischemic stroke | 0.85 [0.73 1.00] | p=0.04 | 0 | 22812 | 2 | WACS vitamin C, PHS II vitamin C, | | Coronary event | 1.04 [0.82 1.33] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Coronary death | no data | | Non fatal MI | 1.09 [0.84 1.40] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | All cause death | 1.05 [0.97 1.14] | p=1.00 | 0 | 22812 | 2 | WACS vitamin C, PHS II vitamin C, | | Non fatal stroke | 0.87 [0.68 1.11] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Haemmorhagic stroke | 0.98 [0.64 1.49] | p=1.00 | 0 | 22812 | 2 | WACS vitamin C, PHS II vitamin C, |
| Trial | Studied treatment | Control | Patients |
|---|
| WACS vitamin C, 2007 | vitamin C (ascorbic acid) 500 mg/d
| placebo
| female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors)
| | PHS II vitamin C, 2008 | vitamin C 500mg daily | placebo | US male physicians aged 50 years or older |
| |
| Vitamin c | cardiovascular prevention, in secondary prevention | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.01 [0.87 1.16] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Cardiovascular death | 1.09 [0.89 1.33] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | stroke (fatal and non fatal) | 0.86 [0.68 1.09] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | ischemic stroke | 0.83 [0.65 1.06] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Coronary event | 1.04 [0.82 1.33] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Coronary death | no data | | Non fatal MI | 1.09 [0.84 1.40] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | All cause death | 1.03 [0.90 1.17] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Non fatal stroke | 0.87 [0.68 1.11] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, | | Haemmorhagic stroke | 1.08 [0.49 2.38] | p=1.00 | 0 | 8171 | 1 | WACS vitamin C, |
| Trial | Studied treatment | Control | Patients |
|---|
| WACS vitamin C, 2007 | vitamin C (ascorbic acid) 500 mg/d
| placebo
| female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors)
|
| |
| Vitamin c | cardiovascular prevention, in primary prevention | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.99 [0.88 1.11] | p=1.00 | 0 | 14641 | 1 | PHS II vitamin C, | | Cardiovascular death | 1.01 [0.85 1.20] | p=1.00 | 0 | 14641 | 1 | PHS II vitamin C, | | stroke (fatal and non fatal) | 0.88 [0.73 1.06] | p=1.00 | 0 | 14641 | 1 | PHS II vitamin C, | | ischemic stroke | 0.87 [0.71 1.06] | p=1.00 | 0 | 14641 | 1 | PHS II vitamin C, | | Coronary event | no data | | Coronary death | no data | | Non fatal MI | no data | | All cause death | 1.06 [0.96 1.18] | p=1.00 | 0 | 14641 | 1 | PHS II vitamin C, | | Non fatal stroke | no data | | Haemmorhagic stroke | 0.94 [0.57 1.54] | p=1.00 | 0 | 14641 | 1 | PHS II vitamin C, |
| Trial | Studied treatment | Control | Patients |
|---|
| PHS II vitamin C, 2008 | vitamin C 500mg daily | placebo | US male physicians aged 50 years or older |
| |
| Vitamin e | cardiovascular prevention, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.99 [0.88 1.11] | p=1.00 | 0 | 15819 | 2 | GISSI, PPP, | | Cardiovascular death | 0.94 [0.80 1.09] | p=1.00 | 0 | 15819 | 2 | GISSI, PPP, | | stroke (fatal and non fatal) | 0.93 [0.71 1.22] | p=1.00 | 0 | 15829 | 2 | GISSI, PPP, | | ischemic stroke | 1.13 [0.59 2.14] | p=1.00 | 0 | 4495 | 1 | PPP, | | Coronary event | 0.89 [0.50 1.59] | p=1.00 | 0 | 4495 | 1 | PPP, | | Coronary death | no data | | Non fatal MI | 1.11 [0.92 1.33] | p=1.00 | 0 | 15819 | 2 | GISSI, PPP, | | All cause death | 0.94 [0.83 1.06] | p=1.00 | 0 | 15829 | 2 | GISSI, PPP, | | Non fatal stroke | 0.95 [0.73 1.26] | p=1.00 | 0 | 15819 | 2 | GISSI, PPP, | | Haemmorhagic stroke | 5.07 [0.24 105.75] | p=1.00 | 0 | 4495 | 1 | PPP, |
| Trial | Studied treatment | Control | Patients |
|---|
| GISSI, 1999 | vitamin E 300mg/d | no vitamine E | patients with recent (3 months) myocardial
infarction | | PPP, 2001 | vitamin E (300 mg/day) | no vitamin E | men and women
aged 50 years or greater, with at least one of the major
recognised cardiovascular risk factors |
| |
| Vitamin e | | vs placebo | Haemmorhagic stroke by 22% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.97 [0.92 1.03] | p=1.00 | 0 | 93072 | 6 | ATBC vitamin E, CHAOS, HOPE, Linxian, WACS vitamin E, PHS II vitamin E, | | Cardiovascular death | 0.99 [0.92 1.05] | p=1.00 | 0 | 93072 | 6 | ATBC vitamin E, CHAOS, HOPE, Linxian, WACS vitamin E, PHS II vitamin E, | | stroke (fatal and non fatal) | 0.98 [0.91 1.06] | p=1.00 | 0 | 101362 | 5 | ATBC vitamin E, HOPE, WACS vitamin E, PHS II vitamin E, WHS vitamin E, | | ischemic stroke | 0.94 [0.86 1.02] | p=1.00 | 0 | 100748 | 5 | ATBC vitamin E, HOPE, WACS vitamin E, PHS II vitamin E, WHS vitamin E, | | Coronary event | 0.92 [0.72 1.17] | p=1.00 | 0 | 8171 | 1 | WACS vitamin E, | | Coronary death | no data | | Non fatal MI | 0.96 [0.85 1.07] | p=1.00 | 0 | 19714 | 3 | CHAOS, HOPE, WACS vitamin E, | | All cause death | 1.03 [0.96 1.11] | p=1.00 | 0 | 30091 | 5 | CHAOS, AREDS, WACS vitamin E, PHS II vitamin E, ASAP, | | Non fatal stroke | 1.01 [0.86 1.18] | p=1.00 | 0 | 17712 | 2 | HOPE, WACS vitamin E, | | Haemmorhagic stroke | 1.22 [1.00 1.48] | p=0.04 | 0 | 100748 | 5 | ATBC vitamin E, HOPE, WACS vitamin E, PHS II vitamin E, WHS vitamin E, |
| Trial | Studied treatment | Control | Patients |
|---|
| ATBC vitamin E, 1994 | vitamin E (alpha-tocopherol) 50mg/d
| placebo
| male smokers 50 to 69 years of age from southwestern Finland
| | CHAOS, 1996 | vitamin E 400-800UI/d (alpha tocopherol) | identical placebo | patients with angiographically proven coronary atherosclerosis | | HOPE, 2000 | vitamin E 400IU/d from natural sources | matching placebo | women and men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor. | | AREDS, 2001 | daily supplementation of antioxidants (500 mg of vitamin C, 400 IU of vitamin E, and 15 mg of beta carotene) | placebo | patients with age-related lens opacities and visual acuity loss | | Linxian, 1993 | beta carotene, vitamin E, and selenium | | Apparently healthy Individuals of ages 40-69 | | WACS vitamin E, 2007 | vitamin E (600IU every two days)
| placebo
| female health professionals at increased
risk (40 years or older with a history of CVD or 3 or more CVD
risk factors)
| | PHS II vitamin E, 2008 | vitamin E 400IU every two days
| placebo
| US male physicians aged 50 years or older | | WHS vitamin E, 2005 | vitamin E 600 IU every other day (á-tocopherol) | placebo | apparently healthy US women aged at least 45 years | | ASAP, 2000 | d-alpha-tocopherol 91 mg (136 IU) twice daily | placebo | smoking and nonsmoking men and postmenopausal women aged 45-69 years with serum cholesterol >= 5.0 mmol/l |
| |
| Vitamin e | cardiovascular prevention, in primary prevention | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.07 [0.73 1.57] | p=1.00 | 0 | 4495 | 1 | PPP, | | Cardiovascular death | 0.86 [0.49 1.52] | p=1.00 | 0 | 4495 | 1 | PPP, | | stroke (fatal and non fatal) | 1.24 [0.66 2.32] | p=1.00 | 0 | 4495 | 1 | PPP, | | ischemic stroke | 1.13 [0.59 2.14] | p=1.00 | 0 | 4495 | 1 | PPP, | | Coronary event | 0.89 [0.50 1.59] | p=1.00 | 0 | 4495 | 1 | PPP, | | Coronary death | no data | | Non fatal MI | 1.07 [0.56 2.05] | p=1.00 | 0 | 4495 | 1 | PPP, | | All cause death | 1.07 [0.77 1.50] | p=1.00 | 0 | 4495 | 1 | PPP, | | Non fatal stroke | 1.56 [0.77 3.15] | p=1.00 | 0 | 4495 | 1 | PPP, | | Haemmorhagic stroke | 5.07 [0.24 105.75] | p=1.00 | 0 | 4495 | 1 | PPP, |
| Trial | Studied treatment | Control | Patients |
|---|
| PPP, 2001 | vitamin E (300 mg/day) | no vitamin E | men and women
aged 50 years or greater, with at least one of the major
recognised cardiovascular risk factors |
| |
| Vitamin e | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.97 [0.91 1.04] | p=1.00 | 0 | 73358 | 3 | ATBC vitamin E, Linxian, PHS II vitamin E, | | Cardiovascular death | 0.98 [0.90 1.05] | p=1.00 | 0 | 73358 | 3 | ATBC vitamin E, Linxian, PHS II vitamin E, | | stroke (fatal and non fatal) | 0.97 [0.89 1.06] | p=1.00 | 0 | 83650 | 3 | ATBC vitamin E, PHS II vitamin E, WHS vitamin E, | | ischemic stroke | 0.92 [0.83 1.02] | p=1.00 | 0 | 83036 | 3 | ATBC vitamin E, PHS II vitamin E, WHS vitamin E, | | Coronary event | no data | | Coronary death | no data | | Non fatal MI | no data | | All cause death | 1.03 [0.94 1.13] | p=1.00 | 0 | 19398 | 2 | AREDS, PHS II vitamin E, | | Non fatal stroke | no data | | Haemmorhagic stroke | 1.19 [0.97 1.47] | p=1.00 | 0 | 83036 | 3 | ATBC vitamin E, PHS II vitamin E, WHS vitamin E, |
| Trial | Studied treatment | Control | Patients |
|---|
| ATBC vitamin E, 1994 | vitamin E (alpha-tocopherol) 50mg/d
| placebo
| male smokers 50 to 69 years of age from southwestern Finland
| | AREDS, 2001 | daily supplementation of antioxidants (500 mg of vitamin C, 400 IU of vitamin E, and 15 mg of beta carotene) | placebo | patients with age-related lens opacities and visual acuity loss | | Linxian, 1993 | beta carotene, vitamin E, and selenium | | Apparently healthy Individuals of ages 40-69 | | PHS II vitamin E, 2008 | vitamin E 400IU every two days
| placebo
| US male physicians aged 50 years or older | | WHS vitamin E, 2005 | vitamin E 600 IU every other day (á-tocopherol) | placebo | apparently healthy US women aged at least 45 years |
| |
| Vitamin e | cardiovascular prevention, in secondary prevention | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.98 [0.87 1.11] | p=1.00 | 0 | 11324 | 1 | GISSI, | | Cardiovascular death | 0.94 [0.80 1.11] | p=1.00 | 0 | 11324 | 1 | GISSI, | | stroke (fatal and non fatal) | 0.87 [0.65 1.18] | p=1.00 | 0 | 11334 | 1 | GISSI, | | ischemic stroke | no data | | Coronary event | no data | | Coronary death | no data | | Non fatal MI | 1.11 [0.91 1.34] | p=1.00 | 0 | 11324 | 1 | GISSI, | | All cause death | 0.92 [0.81 1.05] | p=1.00 | 0 | 11334 | 1 | GISSI, | | Non fatal stroke | 0.87 [0.65 1.18] | p=1.00 | 0 | 11324 | 1 | GISSI, | | Haemmorhagic stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| GISSI, 1999 | vitamin E 300mg/d | no vitamine E | patients with recent (3 months) myocardial
infarction |
| |
| Vitamin e | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.97 [0.90 1.05] | p=1.00 | 0 | 20903 | 5 | CHAOS, HOPE, SPACE, WACS vitamin E, HOPE renal insufficiency subgroup, | | Cardiovascular death | 1.00 [0.90 1.13] | p=1.00 | 0 | 20903 | 5 | CHAOS, HOPE, SPACE, WACS vitamin E, HOPE renal insufficiency subgroup, | | stroke (fatal and non fatal) | 1.02 [0.88 1.18] | p=1.00 | 0 | 18901 | 4 | HOPE, SPACE, WACS vitamin E, HOPE renal insufficiency subgroup, | | ischemic stroke | 0.99 [0.84 1.16] | p=1.00 | 0 | 17908 | 3 | HOPE, SPACE, WACS vitamin E, | | Coronary event | 0.92 [0.79 1.06] | p=1.00 | 0 | 11155 | 4 | SPACE, WACS vitamin E, HOPE renal insufficiency subgroup, ATBC 2nd prev subgroup (vitamin E), | | Coronary death | 1.06 [0.77 1.45] | p=1.00 | 0 | 1795 | 1 | ATBC 2nd prev subgroup (vitamin E), | | Non fatal MI | 0.94 [0.84 1.05] | p=1.00 | 0 | 21509 | 4 | CHAOS, HOPE, WACS vitamin E, ATBC 2nd prev subgroup (vitamin E), | | All cause death | 1.02 [0.91 1.15] | p=1.00 | 0 | 11362 | 4 | CHAOS, SPACE, WACS vitamin E, HOPE renal insufficiency subgroup, | | Non fatal stroke | 1.01 [0.86 1.18] | p=1.00 | 0 | 17712 | 2 | HOPE, WACS vitamin E, | | Haemmorhagic stroke | 1.39 [0.82 2.39] | p=1.00 | 0 | 17712 | 2 | HOPE, WACS vitamin E, |
| Trial | Studied treatment | Control | Patients |
|---|
| CHAOS, 1996 | vitamin E 400-800UI/d (alpha tocopherol) | identical placebo | patients with angiographically proven coronary atherosclerosis | | HOPE, 2000 | vitamin E 400IU/d from natural sources | matching placebo | women and men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor. | | SPACE, 2000 | vitamin E 800 IU daily | matching placebo | Haemodialysis patients aged 40–75 years with pre-existing cardiovascular disease | | WACS vitamin E, 2007 | vitamin E (600IU every two days)
| placebo
| female health professionals at increased
risk (40 years or older with a history of CVD or 3 or more CVD
risk factors)
| | HOPE renal insufficiency subgroup, 2004 | vitamin E 400 IU/day, natural | placebo | patients with either known cardiovascular disease or diabetes and at least one additional coronary risk factor and renal insufficiency (sub group) | | ATBC 2nd prev subgroup (vitamin E), 1998 | alpha tocopherol (vitamin E)
50 mg/day | placebo | patients enroled in the ATBC trial and
who had angina pectoris in the Rose chest
pain questionnaire at baseline |
| |
| Vitamin e | cardiovascular prevention, in patients with renal disease | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.93 [0.71 1.23] | p=1.00 | 0 | 1189 | 2 | SPACE, HOPE renal insufficiency subgroup, | | Cardiovascular death | 0.91 [0.64 1.31] | p=1.00 | 0 | 1189 | 2 | SPACE, HOPE renal insufficiency subgroup, | | stroke (fatal and non fatal) | 1.00 [0.60 1.66] | p=1.00 | 0 | 1189 | 2 | SPACE, HOPE renal insufficiency subgroup, | | ischemic stroke | 0.85 [0.25 2.88] | p=1.00 | 0 | 196 | 1 | SPACE, | | Coronary event | 0.88 [0.64 1.20] | p=1.00 | 0 | 1189 | 2 | SPACE, HOPE renal insufficiency subgroup, | | Coronary death | no data | | Non fatal MI | no data | | All cause death | 0.94 [0.71 1.26] | p=1.00 | 0 | 1189 | 2 | SPACE, HOPE renal insufficiency subgroup, | | Non fatal stroke | no data | | Haemmorhagic stroke | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| SPACE, 2000 | vitamin E 800 IU daily | matching placebo | Haemodialysis patients aged 40–75 years with pre-existing cardiovascular disease | | HOPE renal insufficiency subgroup, 2004 | vitamin E 400 IU/day, natural | placebo | patients with either known cardiovascular disease or diabetes and at least one additional coronary risk factor and renal insufficiency (sub group) |
| |
| Vitamin e | peripheral vascular diseases, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Amputation | 3.00 [0.11 78.40] | p=1.00 | 0 | 40 | 1 | Livingstone, | | stroke (fatal and non fatal) | 0.33 [0.01 8.71] | p=1.00 | 0 | 40 | 1 | Livingstone, | | All cause death | 0.33 [0.01 8.71] | p=1.00 | 0 | 40 | 1 | Livingstone, |
| Trial | Studied treatment | Control | Patients |
|---|
| Livingstone, 1958 | Vitamine E 600 mg /j pendant 40 semaines | Placebo | Selon les grades de Boyd: Grade II: 50%; Grade III: 50%. | | Hamilton, 1953 | Vitamine E naturelle: 450 UI / j pendant 12 semaines. | Placebo: huile darachide | Stade de la maladie: II. |
| |
